Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update

Definium Therapeutics, Inc. (NASDAQ:DFTX) was the target of a significant drop in short interest in the month of March. As of March 13th, there was short interest totaling 15,008,738 shares, a drop of 22.4% from the February 26th total of 19,343,010 shares. Based on an average daily volume of 1,813,075 shares, the days-to-cover ratio is presently 8.3 days. Currently, 15.4% of the company’s stock are short sold.

Definium Therapeutics Stock Down 3.7%

Shares of DFTX stock traded down $0.67 on Monday, hitting $17.21. The company’s stock had a trading volume of 966,828 shares, compared to its average volume of 1,804,162. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -8.08 and a beta of 2.56. Definium Therapeutics has a fifty-two week low of $4.70 and a fifty-two week high of $19.67. The firm’s fifty day moving average price is $17.36 and its 200-day moving average price is $14.05. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.29 and a quick ratio of 6.29.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. raised its stake in shares of Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after acquiring an additional 2,003 shares in the last quarter. BIT Capital GmbH acquired a new position in Definium Therapeutics during the third quarter valued at approximately $26,000. Fifth Third Bancorp raised its position in shares of Definium Therapeutics by 5,593.2% in the third quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock valued at $40,000 after purchasing an additional 3,300 shares during the period. Sound Income Strategies LLC bought a new position in shares of Definium Therapeutics in the third quarter valued at approximately $46,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Definium Therapeutics by 56.0% in the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after buying an additional 3,020 shares during the last quarter. Institutional investors and hedge funds own 27.91% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on DFTX shares. HC Wainwright increased their target price on shares of Definium Therapeutics from $55.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Royal Bank Of Canada boosted their price target on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Needham & Company LLC reiterated a “buy” rating on shares of Definium Therapeutics in a report on Monday, January 5th. Jefferies Financial Group assumed coverage on Definium Therapeutics in a research report on Thursday, January 29th. They set a “buy” rating and a $30.00 price objective for the company. Finally, JonesTrading assumed coverage on Definium Therapeutics in a research note on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $35.70.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.